Video

The Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

Author(s):

Symantha Melemed, PhD

Symantha Melemed, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) in patients with soft tissue sarcoma

Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.

The approval of olaratumab is very exciting to treat advanced soft tissue sarcoma as this is an important advance to patients. It is the first FDA approval in first-line treatment for these patients in 40 years, Melemed explains.

Additionally, sarcoma is a very heterogenous disease comprised of more than 50 subtypes. Other ongoing clinical trials are looking at combination regimens of olaratumab and chemotherapy.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Related Content
FDA
January 10th 2025

GSK’227 Earns FDA Breakthrough Therapy Designation for Late-Line R/R Osteosarcoma

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

R. Lor Randall, MD, FACS
December 5th 2024

Preclinical Data Highlight YAP1 and KRAS as Drivers in Soft Tissue Sarcomas

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
December 29th 2022

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

2rogan – stock.adobe.com
November 12th 2024

Elraglusib Earns FDA Rare Pediatric Disease Designation for Ewing Sarcoma

Pimicotinib in Tenosynovial Giant Cell Tumor | Image Credit: © 2rogan - stock.adobe.com
November 12th 2024

Pimicotinib Meets ORR End Point in Tenosynovial Giant Cell Tumor